EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment

Carolina Muñoz-Grajales, Michelle L Barraclough, Juan P Diaz-Martinez, Jiandong Su, Kathleen Bingham, Mahta Kakvan, Roberta Pozzi Kretzmann, Maria Carmela Tartaglia, Lesley Ruttan, May Y Choi, Simone Appenzeller, Sherief Marzouk und 7 weitere

Frontiers in Immunology · 2024

DOI: 10.3389/fimmu.2023.1326751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2024. Verfasst von Carolina Muñoz-Grajales und 18 weiteren Autor:innen. Beteiligte Einrichtung: Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Despite its frequency, we have a limited understanding of the underlying immune mechanisms, resulting in a lack of pathways to target. This study aims to bridge this gap by investigating differences in serum analyte levels in SLE patients based on their cognitive performance, independently from the attribution to SLE, and exploring the potential for various serum analytes to differentiate between SLE patients with and without CI.

Methods

Two hundred ninety individuals aged 18-65 years who met the 2019-EULAR/ACR classification criteria for SLE were included. Cognitive function was measured utilizing the adapted ACR-Neuropsychological Battery (ACR-NB). CI was defined as a z-score of ≤-1.5 in two or more domains. The serum levels of nine analytes were measured using ELISA. The data were randomly partitioned into a training (70%) and a test (30%) sets. Differences in the analyte levels between patients with and without CI were determined; and their ability to discriminate CI from non-CI was evaluated.

Results

Of 290 patients, 40% (n=116) had CI. Serum levels of S100A8/A9 and MMP-9, were significantly higher in patients with CI (p=0.006 and p=0.036, respectively). For most domains of the ACR-NB, patients with CI had higher S100A8/A9 serum levels than those without. Similarly, S100A8/A9 had a negative relationship with multiple CI tests and the highest AUC (0.74, 95%CI: 0.66-0.88) to differentiate between patients with and without CI.

Conclusion

In this large cohort of well-characterized SLE patients, serum S100A8/A9 and MMP-9 were elevated in patients with CI. S100A8/A9 had the greatest discriminatory ability in differentiating between patients with and without CI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionLupus Erythematosus, SystemicHumansCalgranulin ACalgranulin BMatrix Metalloproteinase 9

Stichwörter der Autor:innen

MMP-9 (matrix metalloproteinase 9)S100A8/A9cognitive impairmentneuropsychiatric systemic lupus erythematosus (NPSLE)systemic lupus erythematosus

Substanzen

Calgranulin ACalgranulin BMatrix Metalloproteinase 9S100A8 protein, humanS100A9 protein, humanMMP9 protein, human

Autor:innen und Institutionen

  • Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada.
  • University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, ON, Canada.
  • National Institute for Health and Care Research (NIHR), Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.
  • Centre for Mental Health, University Health Network, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
  • Department of Medicine, Division of Neurology, University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada.
  • Department of Psychology, University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada.

Zitieren

APA

Muñoz-Grajales, C., Barraclough, M. L., Diaz-Martinez, J. P., Su, J., Bingham, K., Kakvan, M., Kretzmann, R. P., Tartaglia, M. C., Ruttan, L., Choi, M. Y., Appenzeller, S., Marzouk, S., Bonilla, D., Katz, P., Beaton, D., Green, R., Gladman, D. D., Wither, J., & Touma, Z. (2024). Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1326751

Vancouver

Muñoz-Grajales C, Barraclough ML, Diaz-Martinez JP, Su J, Bingham K, Kakvan M, et al. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment. Frontiers in Immunology. 2024. doi:10.3389/fimmu.2023.1326751

BibTeX
@article{MuozGrajales2024,
  author = {Muñoz-Grajales, Carolina and Barraclough, Michelle L and Diaz-Martinez, Juan P and Su, Jiandong and Bingham, Kathleen and Kakvan, Mahta and Kretzmann, Roberta Pozzi and Tartaglia, Maria Carmela and Ruttan, Lesley and Choi, May Y and Appenzeller, Simone and Marzouk, Sherief and Bonilla, Dennisse and Katz, Patricia and Beaton, Dorcas and Green, Robin and Gladman, Dafna D and Wither, Joan and Touma, Zahi},
  title = {Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment},
  journal = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2023.1326751}
}
Kostenlos starten →